Participation is Simple
The RA-BRANCH Study is a pragmatic clinical trial, which aims to measure the relative safety of treatment strategies in real-world clinical practice. The study design puts the focus on patients in the real world. We are looking for clinicians who regularly see adult patients with RA and are interested in participating in a clinical trial. Sign up to receive a Confidentiality Disclosure Agreement (CDA) so you can learn more information about the study design and reimbursement details.
About the RA-BRANCH Study
Rheumatoid arthritis (RA) is a common, systemic autoimmune inflammatory disease, characterized by synovial inflammation leading to pain, swelling, stiffness, and progressive destruction and deformity of small and large joints.
To help evaluate treatment options, we are conducting the RA-BRANCH Study designed to assess the safety of baricitinib in patients with RA receiving routine clinical care. Specifically, the study will compare safety endpoints among patients with RA that are randomized to either TNF inhibitors or baricitinib.Sign-Up Now
1.3 million US adults
are affected by rheumatoid arthritis1
Patients with RA
experience impaired physical function, decreased social participation, health-related quality of life
People with RA have
compared to people in the general population2
1Gabriel et al. 2003 (PMID 12528103); 2Helmick et al 2008 (PMID 18163481)
Frequently Asked Questions
Do I get reimbursed for participating in the study?
Will my patients receive any compensation?
Do I need any previous research experience?
Who is sponsoring the study and why?
What do pragmatic trials matter?
Join the RA-BRANCH Study
Thank you for your interest in this research study. Complete the registration form to be part of this exciting study!
If you have any questions and need more information about the RA-BRANCH Study, please contact us at